Ovarian cancer is a malignant tumor of the female reproductive system, with a very poor
prognosis and high mortality rates. Chemotherapy and radiotherapy are the most common …

Introduction: Endometrial cancer is the most common gynecologic malignancy in the
developed world, and its incidence is increasing. Mortality from this cancer has not improved …

Nivolumab is a human monoclonal antibody against the immune checkpoint receptor
programmed death‐1, inhibiting binding to programmed death‐ligand 1 or 2 (PD‐L1 or PD …

Endometrial cancer is the most common gynecologic malignancy in the United States,
accounting for 6% of cancers in women. In 2017, an estimated 61,380 women were …

Endometrial cancer is the most common cancer of the female reproductive system in the
developed countries. Metformin is a widely used medication that has been prescribed to …

The landscape of diagnosing and treating endometrial cancer is undergoing a profound
transformation due to the integration of molecular analysis and innovative therapeutic …

Advanced and recurrent gynecological cancers lack effective treatment and have poor
prognosis. Besides, there is urgent need for conservative treatment for fertility protection of …

Simple Summary In women, endometrial cancer is a crucial cancer cause-death, which is
still not fully explored in its pathogenesis and immune system. Early detection is essential for …

In the past few years, we have seen several important advances in understanding of and
therapy for endometrial cancer. This review highlights key recent abstracts and publications …

Objective Estrogen is a well-known oncogenic driver in endometrial (ECs) and breast
cancers (BCs). Programmed cell death protein 1 (PD-1) and its ligands PD-1 Ligand 1 (PD …